Pfizer
This study is testing the safety and tolerability of a second dose of Respiratory Syncytial Virus Vaccine (RSVpreF) given approximately 5 years after the initial dose.
Respiratory syncytial virus (RSV) can cause serious respiratory illness in older adults. Previous studies showed that RSVpreF helped protect adults from RSV disease. This study will evaluate the safety of receiving another RSVpreF vaccination about 5 years after an earlier RSVpreF dose. Participants who previously received RSVpreF in Study C3671013 will be assigned to one of three groups: 1. receive a dose RSVpreF revaccination, 2. receive a dose RSVpreF revaccination, or 3. not receive revaccination and continue follow-up. Researchers will evaluate side effects after vaccination and collec…
Key Inclusion Criteria: * Must have participated in the previous Pfizer RSVpreF efficacy study (C3671013) and have been ≥60 years of age at the time of their enrollment in that study. * Must have received their initial RSVpreF dose in the C3671013 study about 5 years prior to enrollment in the current study (C3671087). * Must be determined to be in good health by the investigator, based on medical history and clinical judgment. Participants with stable chronic diseases (e.g., disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before…
Regimen A
Regimen B